TRDA - Entrada Therapeutics jumps 16% after Evercore initiates with an outperform

Evercore ISI analyst Jonathan Miller initiates Entrada Therapeutics (NASDAQ:TRDA) +16% coverage with an outperform rating and no price target. Miller believes that EEV platform is a best-in-class delivery technology seeing preclinical results that "far exceed first-gen constructs" for Duchene Muscular Dystrophy, or DMD. He further adds that the company has presented "the strongest next-gen data presented in DMD so far, noting that it has hit 30%-60% dystrophin production in models, where first-gens managed only low single-digits." He sees "lots of potential" in initial DMD indications, "not to mention all the places they can go from there," the analyst added.

For further details see:

Entrada Therapeutics jumps 16% after Evercore initiates with an outperform